You are here: Industry Insights > psoriatic arthritis

News List

Janssen’s TREMFYA delivers improvement in psoriatic arthritis joint and skin symptoms at week 52 in phase 3 trials pharmaceutical-business-review
June 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2.
AbbVie files Rinvoq for psoriatic arthritis pharmatimes
June 04, 2020
AbbVie is seeking to expand the scope of Rinvoq (upadacitinib) in the US and Europe to include the treatment of adults with active psoriatic arthritis.
Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials pharmaceutical-technology
June 19, 2019
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults with moderate to severe psoriatic arthritis.
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdown fiercepharma
December 19, 2018
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA).
J&J says its psoriasis drug superior to Novartis treatment: Study expressbpd
December 14, 2018
Psoriasis is a chronic condition that causes an overproduction of skin cells, resulting in inflamed, red lesions or plaques, which can be itchy and painful
NICE recommends Eli Lilly's psoriatic arthritis drug pharmafile
August 10, 2018
Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying anti
EU approves Pfizer’s Xeljanz for psoriatic arthritis pharmatimes
July 05, 2018
The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope.
Long-Term Use of Taltz Shows Efficacy Improvements in Psoriatic Arthritis americanpharmaceuticacreview
November 09, 2017
"In addition to the efficacy of Taltz for people with skin symptoms, we are pleased to share new data suggesting that Taltz, if approved, may provide an option for those with joint symptoms of PsA."
BMS's Orencia receives FDA approval for treatment of active psoriatic arthritis in adults cphi-online
July 13, 2017
Orencia now approved in three autoimmune diseases.

Previous page 1 2 3 Next page